文献速递前列腺癌

多参数MRI联合靶向与系统穿刺预测前列腺癌根治术后不良病理特征的价值

The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
PubMed 文献 · Eur Urol · 2019-09-21

该研究纳入614例临床分期≤T2且接受MRI靶向穿刺联合系统穿刺的前列腺癌患者,开发并内部验证预测根治术后包膜外侵犯、精囊侵犯和升级的模型。结果显示联合mp-MRI及两种穿刺信息可提高预测准确性,三个风险计算器在决策曲线分析中净获益最高。

要点

  • mp-MRI联合靶向与系统穿刺信息可提升对包膜外侵犯、精囊侵犯和升级的预测。
  • 省略系统穿刺虽可能减少低危癌检出,但会降低病理特征预测能力。
  • 基于联合信息的风险计算器在决策曲线分析中净获益最高。

核心结论

  • mp-MRI、MRI靶向穿刺及同期系统穿刺均提供识别根治术后不良病理高风险患者的重要信息。
  • 省略系统穿刺会降低准确预测病理特征的能力,尽管可能减少低危癌检出和不适。

研究设计与样本

  • 纳入614例直肠指检临床分期≤T2、接受MRI靶向穿刺联合系统穿刺的男性。
  • 采用逻辑回归开发预测包膜外侵犯、精囊侵犯和升级的模型,并进行内部验证。

主要发现

  • 根治术后包膜外侵犯、精囊侵犯和升级分别发生于333例(54%)、88例(14%)和169例(27%)患者。
  • 加入mp-MRI数据改善临床模型对包膜外侵犯(67% vs 70%)和精囊侵犯(74% vs 76%)的区分度。
  • 联合mp-MRI及靶向与系统穿刺信息的模型内部验证AUC最高:包膜外侵犯73%、精囊侵犯81%、升级73%。

关键数值与推荐

  • 预测包膜外侵犯的联合模型内部验证AUC为73%。
  • 预测精囊侵犯的联合模型内部验证AUC为81%。
  • 预测升级的联合模型内部验证AUC为73%。

临床怎么用

  • 临床可利用基于mp-MRI联合靶向与系统穿刺信息的风险计算器评估不良病理风险。
  • 在MRI靶向穿刺时保留系统穿刺有助于准确预测根治术后病理特征。

局限性

  • 模型仅进行内部验证,未提及外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The combined role of multiparametric magnetic resonance imaging (mp-MRI), and magnetic resonance imaging (MRI)-targeted and concomitant systematic biopsies in the identification of prostate cancer (PCa) patients at a higher risk of adverse pathology at radical prostatectomy (RP) is still unclear. OBJECTIVE: To develop novel models to predict extracapsular extension (ECE), seminal vesicle invasion (SVI), or upgrading in patients diagnosed with MRI-targeted and concomitant systematic biopsies. DESIGN, SETTING, AND PARTICIPANTS: We included 614 men with clinical stage≤T2 at digital rectal examination who underwent MRI-targeted biopsy with concomitant systematic biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Logistic regression analyses predicting ECE, SVI, and upgrading (ie, a shift from biopsy International Society of Urological Pathology grade group to any higher grade at RP) based on clinical variables with or without mp-MRI features and systematic biopsy information (the percentage of cores with grade group ≥2 PCa) were developed and internally validated. The area under the curve (AUC) was used to identify the models with the highest discrimination. Decision-curve analyses (DCAs) determined the net benefit associated with their use. RESULTS AND LIMITATIONS: Overall, 333 (54%), 88 (14%), and 169 (27%) patients had ECE, SVI, and upgrading at RP, respectively. The inclusion of mp-MRI data improved the discrimination of clinical models for ECE (67% vs 70%) and SVI (74% vs 76%). Models including mp-MRI, and MRI-targeted and concomitant systematic biopsy information achieved the highest AUC at internal validation for ECE (73%), SVI (81%), and upgrading (73%) and represented the basis for three risk calculators that yield the highest net benefit at DCA. CONCLUSIONS: Not only mp-MRI and MRI-targeted sampling, but also concomitant systematic biopsies provide significant information to identify patients at a higher risk of adverse pathology. Although omitting systematic prostate sampling at the time of MRI-targeted biopsy might be associated with a reduced risk of detecting insignificant PCa and lower patient discomfort, it reduces the ability to accurately predict pathological features. PATIENT SUMMARY: The combination of multiparametric magnetic resonance imaging (mp-MRI) with accurate biopsy information on MRI-targeted and systematic biopsies improves the accuracy of multivariable models based on clinical and mp-MRI data alone. Correct mp-MRI interpretation and proper extensive prostate sampling are both needed to predict adverse pathology accurately at radical prostatectomy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gandaglia G, Ploussard G, Valerio M, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. Eur Urol. 2019. PMID: 31547938. doi:10.1016/j.eururo.2019.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。